Hexatronic Group har fattat beslut om återköp av egna aktier
Pressmeddelande
17 maj, 2023
Göteborg Sverige
Hexatronic Group har fattat beslut om återköp av egna aktier
Styrelsen i Hexatronic Group AB (publ) (”Hexatronic”) har med stöd av bemyndigandet från årsstämman den 9 maj 2023 beslutat att återköpa maximalt 1 200 000 egna stamaktier på Nasdaq Stockholm under perioden fram till årsstämman 2024.
Syftet med återköpsprogrammet är främst att begränsa utspädning med anledning av bolagets utestående aktiebaserade incitamentsprogram. Syftet är också att kunna använda de återköpta aktierna som betalningsmedel vid eventuella framtida företagsförvärv.
Återköp av egna aktier kommer att genomföras på Nasdaq Stockholm i enlighet med Nordic Main Market Rulebook for Issuers of Shares.
Återköpen kommer att ske enligt följande villkor:
- Återköp får ske vid ett eller flera tillfällen under tiden fram till årsstämman 2024.
- Återköp får ske av högst 1 200 000 aktier.
- Återköp av aktier ska ske på Nasdaq Stockholm till ett pris per aktie inom det vid var tid registrerade kursintervallet, varmed avses intervallet mellan högsta köpkurs och lägsta säljkurs.
- Betalning för aktierna ska erläggas kontant.
Rapportering av återköp kommer att ske till Nasdaq Stockholm i enlighet med gällande regler.
Vid tidpunkten för detta pressmeddelande uppgår det totala antalet aktier i Hexatronic till 205 062 579 aktier, varav 203 026 610 aktier av serie A och 2 035 969 aktier av serie C. Hexatronic innehar vid tidpunkten för detta pressmeddelande 606 300 egna aktier av serie A och 2 035 969 egna aktier av serie C.
Göteborg 17 maj, 2023
Henrik Larsson Lyon
VD Hexatronic Group
För eventuella frågorkontakta:
Henrik Larsson Lyon, VD Hexatronic Group, +46 706 50 34 00
Pernilla Lindén, CFO Hexatronic Group, +46 708 77 58 32
Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 17 maj 2023 kl. 07:00 CEST.
Hexatronic skapar hållbara nätverk över hela världen. Vi samarbetar med kunder på fyra kontinenter – från teleoperatörer till nätverksägare – och erbjuder ledande, högklassig fiberteknik för alla tänkbara användningsområden. Hexatronic Group (publ.) grundades i Sverige 1993 och koncernen är listad på Nasdaq OMX Stockholm. Våra globala varumärken omfattar Viper, Stingray, Raptor, InOne, and Wistom®.
Bilaga
För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.För att se det här innehållet från ml-eu.globenewswire.com måste du ge ditt medgivande sidans topp.
Om
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Följ GlobeNewswire by notified
Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.
Senaste pressmeddelandena från GlobeNewswire by notified
Grant of Restricted Stock Units and Warrants to Employees in Genmab8.6.2023 23:22:17 CEST | Press release
Company Announcement COPENHAGEN, Denmark; June 8, 2023 –Genmab A/S (Nasdaq:GMAB) announced todaythat the Board decided to grant 7,825 restricted stock units and 8,106 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,688. The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the Board of Directors. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Governance > Compensation > Restricted Stock Units. The exercise price fo
Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants8.6.2023 23:19:00 CEST | Press release
FDA Advisory Committee unanimously recommendsnirsevimab as first immunization against RSV disease forall infants Nirsevimab would be the first immunization specifically designed to protect all infants through their first RSV season, if approvedAcross all clinical trials, a single dose of nirsevimab delivered high, consistent and sustained efficacy and favorable safety against RSV diseaseThe FDA has indicated it will work to expedite its review; Sanofi remains committed to delivering nirsevimab in time for the 2023-2024 RSV season Paris, June 8, 2023. The U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously 21 to 0 that Sanofi and AstraZeneca’s nirsevimab has a favorable benefit risk profile for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The Committee also voted 19 to 2 in support of nirsevimab’s favorable benefit ris
DBV Technologies to Participate in Upcoming EAACI Congress 20238.6.2023 22:30:00 CEST | Press release
Montrouge, France, June 8, 2023 DBV Technologies to Participate in Upcoming EAACI Congress 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 9 – 11, 2023, in Hamburg, Germany. DBV will present three posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presented during the scientific sessions will describe the current burden of peanut allergy and treatment management strategies for children in the U.K. DBV will also present data from its completed EPITOPE Phase 3 study assessing the efficacy and safety of epicutaneous immunotherapy (EPIT) using Viaskin Peanut™ in toddlers aged 1-3 years with or without concomitant asthma. The toddler age-group represents the age range in which many peanut-allergic children are diagnosed, yet there are currently n
GOGL - Transactions made under the buy-back program8.6.2023 22:30:00 CEST | Press release
Reference is made to the stock announcement on October 4, 2022, where Golden Ocean Group Limited (OSE/NASDAQ: GOGL) announced the commencement of its share buy-back program of maximum USD 100 million to purchase up to an aggregate of 10,000,000 of the company's common shares in a 12-month period from the announcement. Golden Ocean Group Limited (“GOGL” or the “Company”) announces that the Company has during the week ending Friday June 2, 2023, purchased 25,343 of the Company’s own common stocks. 343 of the shares have been bought on the Oslo Stock Exchange at an average price of NOK 80.00 per share and 25,000 of the shares have been bought on Nasdaq at an average price of USD 7.19 per share. Following the completion of the above transactions, GOGL owns a total of 952,428 of own shares, corresponding to 0.47% of the Company’s share capital. An overview of all transactions made under the buy-back program that have been carried out during the above-mentioned date is attached to this repor
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants8.6.2023 22:00:00 CEST | Press release
Company announcement – No. 25 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, June 8, 2023– Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 36,006 divided into 36,006 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma share at a prespecified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand Pharma’s warrant programs, see the company’s Articles of Association, which are